Stephanie Geisler

19.2k citations

36 papers · 14.5k indexed · 4 hit papers · h-index 21

Molecular Biology top 0.5%
Oncology top 0.1%
Cancer Research top 0.05%
Genetics top 0.5%
Pathology and Forensic Medicine top 0.5%

Co-authors: Per Eystein Lønning Hilde Johnsen Anne‐Lise Børresen‐Dale Thérese Sørlie Charles M. Perou David Botstein Patrick O. Brown Robert Tibshirani
Topics: Breast Cancer Treatment Studies (11 papers)Cancer-related Molecular Pathways (11 papers)Cancer Genomics and Diagnostics (5 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Proceedings of the National Academy of Sciences Nature Medicine Nature Genetics
Partner nations: Norway United Kingdom United States

In The Last Decade

Stephanie Geisler

35 papers receiving 14.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

2001 8.3k citations Thérese Sørlie, Charles M. Perou et al. profile →
Repeated observation of breast tumor subtypes in independent gene expression data sets

2003 4.0k citations Thérese Sørlie, Andrew B. Nobel et al. profile →
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1996 608 citations Turid Aas, Anne‐Lise Børresen et al. Nature Medicine profile →
Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays

1999 531 citations Charles M. Perou, Thérese Sørlie et al. profile →

Peers

Countries citing papers authored by Stephanie Geisler

Since Specialization

Citations

This map shows the geographic impact of Stephanie Geisler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephanie Geisler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephanie Geisler more than expected).

Fields of papers citing papers by Stephanie Geisler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephanie Geisler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephanie Geisler. The network helps show where Stephanie Geisler may publish in the future.

Co-authorship network of co-authors of Stephanie Geisler

This figure shows the co-authorship network connecting the top 25 collaborators of Stephanie Geisler. A scholar is included among the top collaborators of Stephanie Geisler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephanie Geisler. Stephanie Geisler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane 2024 ·Breast Cancer Research and Treatment ·(unknown),Bjørg Almås,(unknown),Kristin Viste,Stephanie Geisler,Torill Sauer,(unknown),Jürgen Geisler	0
2	Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development 2023 ·Genome Medicine ·Oleksii Nikolaienko,Hans Petter Eikesdal,(unknown),Bjørnar Gilje,Steinar Lundgren,Egil Støre Blix,(unknown),Jürgen Geisler,Stephanie Geisler,Emiel A. M. Janssen,Synnøve Yndestad,Laura Minsaas,Beryl Leirvaag,Reidun Lillestøl,Stian Knappskog,Per Eystein Lønning	13
3	Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy 2022 ·Genome Medicine ·(unknown),(unknown),Wei Deng,Jürgen Geisler,Stephanie Geisler,(unknown),Turid Aas,Hildegunn S. Aase,(unknown),(unknown),Ola Myklebost,Sigve Nakken,Daniel Vodák,Eivind Hovig,Leonardo A. Meza‐Zepeda,Per Eystein Lønning,Stian Knappskog,Hans Petter Eikesdal	10
4	The Iliofemoral tortuosity score predicts access and bleeding complications during transfemoral transcatheter aortic valve replacement: Data from the VIenna Cardio Thoracic aOrtic valve registrY (VICTORY) 2021 ·European Journal of Clinical Investigation ·Markus Mach,(unknown),Waseem Hasan,(unknown),Martin Andreas,Bernhard Winkler,Stephanie Geisler,Daniela Geisler,Piotr Nikodem Rudziński,(unknown),(unknown),Christopher Adlbrecht,Georg Delle‐Karth,Martin Grabenwöger	21
5	Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin 2021 ·Breast Cancer Research and Treatment ·(unknown),(unknown),Andliena Tahiri,Torill Sauer,(unknown),Stephanie Geisler,Berit Gravdehaug,(unknown),(unknown),Vessela N. Kristensen,Jürgen Geisler	10
6	A rare case of a subungual epidermoid cyst treated by surgical excision maintaining maximal functionality 2020 ·JAAD Case Reports ·Stephanie Geisler,Volker Steinkraus,(unknown)	1
7	The NEOLETEXE Trial: A Neoadjuvant Cross-Over Study Exploring the Lack of Cross Resistance Between Aromatase Inhibitors 2019 ·Future Oncology ·(unknown),Torill Sauer,(unknown),(unknown),Vahid Bemanian,Jonas Christoffer Lindstrøm,Torben Lüders,Vessela N. Kristensen,(unknown),(unknown),(unknown),(unknown),(unknown),Stephanie Geisler,Berit Gravdehaug,(unknown),Jürgen Geisler	8
8	Short-Term Efficacy of Trichloroacetic Acid in the Treatment of Cervical Intraepithelial Neoplasia 2016 ·Obstetrics and Gynecology ·Stephanie Geisler,(unknown),(unknown),Georg Heinze,Adam Rosenthal,P Speiser	12
9	Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer 2011 ·British Journal of Cancer ·Lars A. Akslen,Oddbjørn Straume,Stephanie Geisler,Thérese Sørlie,Jen‐Tsan Chi,Turid Aas,(unknown),Per Eystein Lønning	13
10	Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers 2010 ·Molecular Cancer ·(unknown),Stian Knappskog,Stephanie Geisler,Vidar Staalesen,(unknown),Anne‐Lise Børresen‐Dale,Pål Puntervoll,Johan R. Lillehaug,Per Eystein Lønning	26
11	DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response 2010 ·Molecular Cancer ·Emelyne Dejeux,Jo Anders Rønneberg,Hiroko Kato Solvang,I. K. Bukholm,Stephanie Geisler,Turid Aas,Marta Gut,Anne‐Lise Børresen‐Dale,Per Eystein Lønning,Vessela N. Kristensen,Jörg Tost	103
12	A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide 2009 ·Clinical Cancer Research ·Sharon A. Glynn,Brenda J. Boersma,Tiffany M. Howe,Hege Edvardsen,Stephanie Geisler,Julie E. Goodman,Lisa A. Ridnour,Per Eystein Lønning,Anne‐Lise Børresen‐Dale,Bjørn Naume,Vessela N. Kristensen,Stephen J. Chanock,David A. Wink,Stefan Ambs	38
13	ABCB1 and GST polymorphisms associated with TP53 status in breast cancer 2007 ·Pharmacogenetics and Genomics ·Silje Nord,Marylyn D. Ritchie,(unknown),Alison A. Motsinger‐Reif,Grethe I.G. Alnæs,Gordon Lemmon,Marianne Berg,Stephanie Geisler,Jason H. Moore,Per Eystein Lønning,Anne‐Lise Børresen‐Dale,Vessela N. Kristensen	27
14	Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer 2006 ·Molecular Cancer Therapeutics ·Thérese Sørlie,Charles M. Perou,Huihui Fan,Stephanie Geisler,Turid Aas,Andrew B. Nobel,Gun Anker,Lars A. Akslen,David Botstein,Anne‐Lise Børresen‐Dale,Per Eystein Lønning	97
15	Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. 2006 ·Molecular Cancer ·Lars O. Baumbusch,Simen Myhre,Anita Langerød,Anna Bergamaschi,Stephanie Geisler,Per Eystein Lønning,Wolfgang Deppert,(unknown),Anne‐Lise Børresen‐Dale	20
16	The murine Dnali1 gene encodes a flagellar protein that interacts with the cytoplasmic dynein heavy chain 1 2006 ·Molecular Reproduction and Development ·Sajid Rashid,(unknown),Mike Hupe,Stephanie Geisler,(unknown),Jürgen Neesen	38
17	Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. 2001 ·PubMed ·Stephanie Geisler,Per Eystein Lønning,Turid Aas,Hilde Johnsen,Øystein Fluge,Dagny Faksvåg Haugen,J.R. Lillehaug,Lars A. Akslen,Anne‐Lise Børresen‐Dale	264
18	Effects of treatment with megestrol acetate on the insulin-like growth factor system: time and dose dependency 1999 ·European Journal of Cancer ·Svein Inge Helle,Steinar Lundgren,Stephanie Geisler,Dagfinn Ekse,Jeff M.P. Holly,Per Eystein Lønning	8
19	Absence of p21 expression is associated with abnormal p53 in human breast carcinomas 1997 ·British Journal of Cancer ·PA Ellis,Per Eystein Lønning,A.L. Børresen-Dale,Turid Aas,Stephanie Geisler,(unknown),(unknown),(unknown),Mitch Dowsett	33
20	Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsbreakdown → 1996 ·Nature Medicine ·Turid Aas,Anne‐Lise Børresen,Stephanie Geisler,Birgitte Smith‐Sørensen,Hilde Johnsen,Jan Erik Varhaug,Lars A. Akslen,Per Eystein Lønning	608

About Stephanie Geisler

Stephanie Geisler is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 36 papers that have together received 14.5k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (11 papers), Cancer-related Molecular Pathways (11 papers) and Cancer Genomics and Diagnostics (5 papers). The work is most often cited by research in Cancer Research (7.2k citations), Oncology (7.4k citations) and Molecular Biology (7.5k citations). Stephanie Geisler has collaborated with scholars based in Norway, United Kingdom and United States. Frequent co-authors include Per Eystein Lønning, Hilde Johnsen, Anne‐Lise Børresen‐Dale, Thérese Sørlie, Charles M. Perou, David Botstein, Patrick O. Brown, Robert Tibshirani, Trevor Hastie and Turid Aas. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact